Cannabinoid receptor 2-deficiency ameliorates disease symptoms in a mouse model 
with Alzheimer's disease-like pathology

Schmoele, Anne-Caroline; Lundt, Ramona; Toporowski, Gregor; Hansen, Jan N.; Beins, Eva; Halle, Annett; Zimmer, Andreas

doi:10.3233/JAD-180230

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Cannabinoid receptor 2-deficiency ameliorates disease symptoms in a mouse model with Alzheimer's disease-like pathology

MPS-Authors

Hansen, Jan N.
Max Planck Research Group Neuroimmunology, Center of Advanced European Studies and Research (caesar), Max Planck Society;

Halle, Annett
Max Planck Research Group Neuroimmunology, Center of Advanced European Studies and Research (caesar), Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Schmoele, A.-C., Lundt, R., Toporowski, G., Hansen, J. N., Beins, E., Halle, A., et al. (2018). Cannabinoid receptor 2-deficiency ameliorates disease symptoms in a mouse model with Alzheimer's disease-like pathology. Journal of Alzheimer's Disease, 64(2), 379-392. doi:10.3233/JAD-180230.

Cite as: https://hdl.handle.net/21.11116/0000-0003-4AD3-C

Abstract

It is widely accepted that the endocannabinoid system (ECS) is a modulator of neuroinflammation associated with neurodegenerative disorders, including Alzheimer's disease (AD). Thus, expression of the cannabinoid receptor 2 (CB2) is induced in plaque-associated microglia and astrocytes in brain tissues from AD patients and in genetic mouse models expressing pathogenic variants of the amyloid precursor protein (APP). However, the exact mechanism of CB2 signaling in this mouse model remains elusive, because the genetic deletion of CB2 and the pharmacological activation of CB2 both reduced neuroinflammation. Here, we demonstrate that CB2 deletion also improved cognitive and learning deficits in APP/PS1*CB2(-/-) mice. This was accompanied by reduced neuronal loss and decreased plaque levels and coincided with increased expression of A beta degrading enzymes. Interestingly, plaque-associated microglia in APP/PS1*CB2(-/-) mice showed a less activated morphology, while plaques were smaller and more condensed than in APP/PS1 mice. Taken together, these results indicate a beneficial effect of CB2-deficiency in APP transgenic mice. CB2 appears to be part of a protective system that may be detrimental when engaged continuously.